Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has successfully completed the Maintenance and Transition phases of Study VRX-RET-E22-302 for the treatment of partial-onset seizures~* Patient is expected to benefit from participation in the study in the opinion of the Investigator.~Exclusion Criteria:~* Patient meets any of the withdrawal criteria in the previous VRX-RET-E22-302 study or is experiencing an ongoing serious adverse event.~* Patient is receiving any investigational drug or using any experimental device in addition to Retigabine for treatment of epilepsy or any other medical condition.~* Patient has any other condition that would prevent compliance with the study procedures or proper reporting of adverse events.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Retigabine (INN), Ezogabine (USAN) (Type: EXPERIMENTAL): Retigabine (Ezogabine): all subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).